Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community.
A double-blind controlled trial of a 14-valent pneumococcal polysaccharide vaccine was carried out in 11 958 adults at Tari in the Papua New Guinea Highlands. Pneumococcal infection, confirmed by blood-culture and lung aspirate, was less in the vaccinated group by 84%. Mortality from pneumonia was less by 44%.
D000328:Adult; D000907:Antibodies, Bacterial / Q000302:isolation & purification; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006801:Humans; D008168:Lung / Q000382:microbiology; D009512:New Guinea; D009666:Nose / Q000382:microbiology; D011018:Pneumonia, Pneumococcal / Q000382:microbiology / Q000401:mortality / Q000517:prevention & control*; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage / Q000627:therapeutic use; D018805:Sepsis / Q000382:microbiology; D013183:Sputum / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000276:immunology* / Q000302:isolation & purification
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D011135:Polysaccharides, Bacterial